Cost-Effectiveness of Interventions to Reduce Vertical HIV Transmission from Pregnant Women Who Have Not Received Prenatal Care

Medical Decision Making

Volumn 24, Issue 1, 2004, Pages 30-39

  Mrus, Joseph M ^a,b   Tsevat, Joel ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; HIV; Testing; Vertical transmission

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; NEWBORN; NONHUMAN; PREGNANCY; PRENATAL CARE; PROPHYLAXIS; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; VERTICAL TRANSMISSION; VIRUS DIAGNOSIS; VIRUS TRANSMISSION;

AIDS SERODIAGNOSIS; ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DELIVERY, OBSTETRIC; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PRENATAL DIAGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RISK; ZIDOVUDINE;

EID: 1642566149     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X03261570     Document Type: Article

References (41)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-80.
2. Fiscus SA, Schoenbach VJ, Wilfert C. Short courses of zidovudine and perinatal transmission of HIV. N Engl J Med. 1999;340:1040-1.
3. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409-14.
4. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
5. Ventura SJ, Martin JA, Mathews TJ, Clarke SC. Advance report of final natality statistics, 1994. Monthly Vital Statistics Report. 1996; 44:67.
6. Ventura SJ, Martin JA, Curtin SC, Mathews TJ. Report of final natality statistics, 1996. Monthly Vital Statistics Report. 1998;46:69.
7. Ventura SJ, Martin JA, Curtin SC, et al. Births: final data for 1998. National Vital Statistics Report. 2000;48:65.
8. Lindsay MK, Feng TI, Peterson HB, et al. Routine human immunodeficiency virus infection screening in unregistered and registered inner-city parturients. Obstet Gynecol. 1991;77:599-603.
9. Donegan SP, Steger KA, Recla L, et al. Seroprevalence of human immunodeficiency virus in parturients at Boston City Hospital: implications for public health and obstetric practice. Am J Obstet Gynecol. 1992;167:622-9.
10. Murex. Summary Basis of Approval. Bethesda (MD): Food and Drug Administration, US Department of Health and Human Services; 1992.
11. Rajegowda BK, Das BB, Lala R, et al. Expedited human immunodeficiency virus testing of mothers and newborns with unknown HIV status at time of labor and delivery. J Perinat Med. 2000;28:458-63.
12. Grobman WA, Garcia PM. The cost-effectiveness of voluntary intrapartum rapid human immunodeficiency virus testing for women without adequate prenatal care. Am J Obstet Gynecol. 1999; 181:1062-71.
13. Stringer JS, Rouse DJ. Rapid testing and zidovudine treatment to prevent vertical transmission of human immunodeficiency virus in unregistered parturients: a cost-effectiveness analysis. Obstet Gynecol. 1999;94:34-40.
14. Perinatal HIV Guidelines Working Group. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States: February 25, 2000. HIV Clin Trials. 2000;1:39-64.
15. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1-a meta-analysis of 15 prospective cohort studies. The International Perinatal HIV Group. N Engl J Med. 1999;340:977-87.
16. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
17. Mrus JM, Goldie SJ, Weinstein MC, Tsevat J. The cost-effectiveness of elective cesarean delivery for HIV-infected women with detectable HIV RNA during pregnancy. AIDS. 2000;14:2543-52.
18. Mauskopf JA, Paul JE, Wichman DS, et al. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. JAMA. 1996;276:132-8.
19. Gwinn M, Pappaioanou M, George JR, et al. Prevalence of HIV infection in childbearing women in the United States. Surveillance using newborn blood samples. JAMA. 1991;265:1704-8.
20. Davis SF, Byers RH Jr, Lindegren ML, et al. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA. 1995;274:952-5.
21. Myers ER, Thompson JW, Simpson K. Cost-effectiveness of mandatory compared with voluntary screening for human immunodeficiency virus in pregnancy. Obstet Gynecol. 1998;91:174-81.
22. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet. 1999;353:781-5.
23. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet. 1999;353:773-80.
24. Laboratory tests. In: Bartlett JG, Gallant JE, eds. Medical Management of HIV Infection. Baltimore: Port City Press; 2001. p 5-30.
25. Kelen GD, Shahan JB, Quinn TC. Emergency department-based HIV screening and counseling: experience with rapid and standard serologic testing. Ann Emerg Med. 1999;33:147-55.
26. Irwin K, Olivo N, Schable CA, et al. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. CDC-Bronx-Lebanon HIV Serosurvey Team. Ann Intern Med. 1996;125:471-5.
27. Malone JD, Smith ES, Sheffield J, et al. Comparative evaluation of six rapid serological tests for HIV-1 antibody. J Acquir Immune Defic Syndr. 1993;6:115-9.
28. Centers for Disease Control and Prevention. Update: HIV counseling and testing using rapid tests-United States, 1995. MMWR. 1998;47:211-5.
29. Hsia DC, Fleishman JA, East JA, Hellinger FJ. Pediatric human immunodeficiency virus infection. Recent evidence on the utilization and costs of health services. Arch Pediatr Adolesc Med. 1995; 149:489-96.
30. Medical Economics. Drug Topics Red Book. Montvale (NJ): Medical Economics; 2000.
31. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995;26:914-9.
32. Rawlings JE, Holmes J, Belton B, et al. Changes in HIV/AIDS patterns of care and estimated costs at an urban medical center during the era of HAART. Paper presented at the 12th World AIDS Conference, Geneva, Switzerland; 1998.
33. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16:54-62.
34. Havens PL, Cuene BE, Holtgrave DR. Lifetime cost of care for children with human immunodeficiency virus infection. Pediatr Infect Dis J. 1997;16:607-10.
35. Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279:130-6.
36. Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health. 2001;91:1456-63.
37. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
38. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIV-infected patients. Ann Intern Med. 1999;131:194-8.
39. Minino AM, Smith BL. Deaths: preliminary data for 2000. National Vital Statistics Report. 2001;49:1-40.
40. Shapiro D, Tuomala R, Samelson R, et al. Antepartum antiretroviral therapy and pregnancy outcomes in 462 HIV-infected women in 1998-1999 (PACTG 367) #664. Paper presented at the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco; 2000: Abstract available from: http://www.retroconference. org/2000/abstracts/664.htm.
41. Farnham PG, Gorsky RD, Holtgrave DR, Jones WK, Guinan ME. Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests. Public Health Rep. 1996; 111:44-53.